Page last updated: 2024-08-21

pyrazines and HbS Disease

pyrazines has been researched along with HbS Disease in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	12 (20.69)	24.3611
2020's	46 (79.31)	2.80

Authors

Authors	Studies
Betancourt, J; Campbell, S; Curtis, SA; Kottapalli, N; Minniti, C	1
Lemon, N; Rech, MA; Sterk, E	1
Cimpeanu, E; Dutta, D; Jafri, F; Leibovitch, JN; Lim, SH; Poplawska, M; Tambe, AV	1
Gordeuk, VR; Han, J; Hussain, F; Molokie, RE; Njoku, F; Saraf, SL	1
Çanak, B; Eşkazan, AE	1
Boyd, S; Denny, N; Howard, J; Jackson, E; Lugthart, S; Roy, NBA; Vora, SM	1
Agodoa, I; Alvarez, O; Beaubrun, A; Delea, T; Lipato, T; Lonshteyn, A; Nguyen, A; Shah, N; Weycker, D	1
Bain, BJ; Hann, A; Layton, DM; Myburgh, J	1
Green, ML; Jorga, K; Savic, RM; Washington, CB; Zager, M	1
Green, ML; Jorga, K; Savic, RM; Tonda, M; Washington, CB	1
Abboud, MR; Brown, C; Campbell, A; Dixon, S; Estepp, JH; Griffin, NM; Inati, A; Inusa, BPD; Kalpatthi, R; Liem, RI; Piccone, C; Sims, K; Smith-Whitley, K; Tonda, M; Trompeter, S; Washington, C; Woods, G	1
Anderson, AR; Fuqua, T; Muschick, K; Stoker-Postier, C	1
Abboud, MR; Brown, C; Tonda, M	1
Kanter, J; Nagalapuram, V	1
Haque, A; Idowu, M; Sridhar, A; Williams, EM	1
Fasipe, TA; Kavanagh, PL; Wun, T	1
Bade, NA; Ershler, WB; Giri, U; Wang, H	1
Ferlis, M; Lipato, T; Roseff, SD; Smith, WR	1
Springer, G	1
Ferrone, FA	1
Anamelechi, JP; Ayoola, SO; Badmus, IO; Boyenle, ID; Elegbeleye, OE; Falusi, AG; Joshua, KI; Manica, AK; Odetunde, A; Ogbonna, HN; Ogunlana, AT; Ojo, TO; Onikute, OW; Oyedele, AK; Quadri, BO	1
Wadman, M	1
Steinberg, MH	2
Aschenbrenner, DS	1
Lettre, G	1
Gordeuk, VR; Han, J; Saraf, SL	1
Fantasia, HC; Morse, BL	1
Chan, KC; Das, BB; Jadotte, MM	1
Campbell, ST; Colby, JM; Rutherford-Parker, NJ; Shajani-Yi, Z	1
Herity, LB; Lowe, DK; Rodriguez, LR; Vaughan, DM	1
Ershler, WB; Holbrook, ME	1
Colby, JM; Shajani-Yi, Z	1
Lehrer-Graiwer, J; Love, TW; Tong, B; Yokoshima, L	1
Abdulmalik, O; El-Araby, ME; Ghatge, MS; Muhammad, YA; Omar, AM; Paredes, SD; Safo, MK	1
Brewin, JN; Gibson, JS; Hannemann, A; Rees, DC; Wadud, R	1
Erkurt, MA; Parlakpinar, H; Sarici, A; Tanriverdi, LH	1
Biemond, BJ; Gray, S; Knight-Madden, J; Lehrer-Graiwer, J; Minniti, CP; Tonda, M	1
Ataga, KI; Brugnara, C; Staffa, SJ; Stocker, JW	1
Vichinsky, E; Vissa, M	1
Abukar, J; Benson, S; Braimoh, A; Kamal, M; Tsitsikas, DA	1
Archer, N; Campbell, A; Casale, M; Inusa, BPD	1
Achebe, M; Agodoa, I; Ataga, KI; Brown, RC; El-Beshlawy, A; Gray, S; Hassab, H; Howard, J; Lehrer-Graiwer, J; Nduba, V; Tonda, M; Vichinsky, E	1
Anderson, MR; Godbey, EA; M Bachmann, L; Roseff, SD; Sanford, KW; Wieditz, K	1
Booth, GS	1
Ballas, SK; Gordeuk, VR; Hankins, JS; Kuypers, FA; Thompson, AA; Vichinsky, E	1
Best, RB; Bunn, HF; Cellmer, T; Conrey, A; Dunkelberger, EB; Eaton, WA; Glass, KE; Harper, J; Henry, ER; Li, Q; Metaferia, B; Thein, SL	1
Hebbel, RP; Hedlund, BE	1
Estepp, JH	1
Colby, JM; Rutherford, NJ; Shajani-Yi, Z; Thoren, KL	1
Alayash, AI; Eaton, WA; Gwaabe, E; Harper, J; Henry, ER; Mendelsohn, L; Nichols, J; Ostrowski, D; Shet, AS; Thein, SL	1
Awogbade, M; Dixon, S; Dufu, K; Gretler, DD; Hemmaway, CJ; Howard, J; Hutchaleelaha, A; Landsman, N; Layton, DM; Lehrer-Graiwer, J; Mant, T; Patel, M; Porter, J; Siu, V; Telfer, P; Tonda, M	1
Allen, E; Gretler, DD; Hutchaleelaha, A; Lehrer-Graiwer, J; Mant, T; Oksenberg, D; Patel, M; Siu, V; Washington, C	1
Abdulmalik, O; Bartels, M; Bos, J; Cnossen, MH; Houwing, ME; Merkx, TH; Pasterkamp, G; Rab, MAE; Riedl, J; Safo, MK; Schutgens, REG; van Beers, EJ; van Oirschot, BA; van Wesel, ACW; van Wijk, R; Versluijs, BA	1
Alayash, AI; Eaton, WA; Harper, J; Henry, ER; Liang, H; Meng, F; Ostrowski, DA; Shet, AS; Strader, MB; Thein, SL	1
Abboud, MR; Achebe, MM; Alkindi, S; Ataga, KI; Brown, RC; Diuguid, DL; El-Beshlawy, A; Elghandour, A; Gordeuk, VR; Hassab, H; Hoppe, CC; Howard, J; Intondi, A; Kanter, J; Lehrer-Graiwer, J; Nduba, V; Telfer, P; Tonda, M; Tong, B; Tsitsikas, DA; Vichinsky, E; Ware, RE	1
Johnson, CS; Kalra, VK; Meng, Z; Pullarkat, V; Tahara, SM	1

Reviews

7 review(s) available for pyrazines and HbS Disease

Article	Year
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope? Blood reviews, 2022, Volume: 53 Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Glutamine; Hematopoietic Stem Cell Transplantation; Humans; Pyrazines; Pyrazoles	2022
Voxelotor for the treatment of sickle cell disease in pediatric patients. Expert review of hematology, 2022, Volume: 15, Issue:6 Topics: Adult; Anemia, Sickle Cell; Benzaldehydes; Child; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles	2022
Sickle Cell Disease: A Review. JAMA, 2022, 07-05, Volume: 328, Issue:1 Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; Child; Glutamine; Hematologic Agents; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infant, Newborn; Neonatal Screening; Pain; Pyrazines; Pyrazoles; Transition to Adult Care; United States	2022
Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. Pharmacotherapy, 2020, Volume: 40, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Biomarkers; Dose-Response Relationship, Drug; Hematologic Agents; Hemoglobin, Sickle; Humans; Polymerization; Pyrazines; Pyrazoles; Randomized Controlled Trials as Topic	2020
Voxelotor: A Novel Treatment for Sickle Cell Disease. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:2 Topics: Anemia, Sickle Cell; Benzaldehydes; Female; Hematologic Agents; Hemoglobins; Humans; Hydroxyurea; Male; Pyrazines; Pyrazoles; Treatment Outcome; Young Adult	2021
The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials. International journal of clinical practice, 2021, Volume: 75, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Multicenter Studies as Topic; Prospective Studies; Pyrazines; Pyrazoles; Randomized Controlled Trials as Topic	2021
Voxelotor for the treatment of sickle cell disease. Expert review of hematology, 2021, Volume: 14, Issue:3 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Pyrazines; Pyrazoles	2021

Trials

5 trial(s) available for pyrazines and HbS Disease

Article	Year
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Haematology, 2021, Volume: 8, Issue:5 Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genotype; Headache; Hemoglobin, Sickle; Hemoglobins; Humans; Male; Middle Aged; Placebo Effect; Pyrazines; Pyrazoles; Treatment Outcome; Young Adult	2021
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood, 2019, 04-25, Volume: 133, Issue:17 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzaldehydes; Case-Control Studies; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Hematologic Agents; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrazines; Pyrazoles; Tissue Distribution; Young Adult	2019
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. British journal of clinical pharmacology, 2019, Volume: 85, Issue:6 Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Double-Blind Method; Erythrocytes; Female; Humans; London; Male; Middle Aged; Models, Biological; Oxyhemoglobins; Pyrazines; Pyrazoles; San Francisco; Treatment Outcome; Young Adult	2019
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. The New England journal of medicine, 2019, 08-08, Volume: 381, Issue:6 Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Biomarkers; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemoglobin, Sickle; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intention to Treat Analysis; Male; Middle Aged; Polymerization; Pyrazines; Pyrazoles; Young Adult	2019
Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway. Hemoglobin, 2014, Volume: 38, Issue:3 Topics: Active Transport, Cell Nucleus; Anemia, Sickle Cell; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Nucleus; Erythroid Precursor Cells; Female; Fetal Hemoglobin; Humans; K562 Cells; Male; NF-E2-Related Factor 2; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic	2014

Other Studies

46 other study(ies) available for pyrazines and HbS Disease

Article	Year
Voxelotor use in adults with sickle cell disease in a real-world setting. American journal of hematology, 2022, 03-01, Volume: 97, Issue:3 Topics: Adult; Anemia, Sickle Cell; Benzaldehydes; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Pyrazoles; Retrospective Studies; Survival Rate	2022
Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease. The American journal of emergency medicine, 2022, Volume: 55 Topics: Anemia, Sickle Cell; Benzaldehydes; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles; Venous Thromboembolism; Venous Thrombosis	2022
Voxelotor and albuminuria in adults with sickle cell anaemia. British journal of haematology, 2022, Volume: 197, Issue:5 Topics: Adult; Albuminuria; Anemia, Sickle Cell; Benzaldehydes; Humans; Pyrazines; Pyrazoles	2022
Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease. British journal of clinical pharmacology, 2022, Volume: 88, Issue:6 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Humans; Hydroxyurea; Pyrazines; Pyrazoles	2022
Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor. British journal of haematology, 2022, Volume: 197, Issue:4 Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Humans; Pyrazines; Pyrazoles; United Kingdom	2022
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert review of hematology, 2022, Volume: 15, Issue:2 Topics: Anemia, Sickle Cell; Benzaldehydes; Data Analysis; Hemoglobins; Humans; Pyrazines; Pyrazoles; Quality of Life	2022
Voxelotor in sickle cell disease. American journal of hematology, 2022, 06-01, Volume: 97, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Pyrazines; Pyrazoles	2022
Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:6 Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Drug Development; Humans; Models, Biological; Pyrazines; Pyrazoles	2022
Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:6 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzaldehydes; Drug Development; Hemoglobin, Sickle; Hemoglobins; Hemolysis; Humans; Pyrazines; Pyrazoles	2022
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatric blood & cancer, 2022, Volume: 69, Issue:8 Topics: Anemia, Sickle Cell; Benzaldehydes; Biomarkers; Child; Child, Preschool; Female; Hemoglobin, Sickle; Hemolysis; Humans; Male; Pyrazines; Pyrazoles	2022
Real-world data on voxelotor to treat patients with sickle cell disease. European journal of haematology, 2022, Volume: 109, Issue:2 Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Benzaldehydes; Bilirubin; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Pyrazines; Pyrazoles; Retrospective Studies; Young Adult	2022
Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease. American journal of hematology, 2022, Volume: 97, Issue:8 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Multiple Organ Failure; Pyrazines; Pyrazoles	2022
Patient perception of voxelotor treatment benefit in sickle cell disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:5 Topics: Anemia, Sickle Cell; Benzaldehydes; Hemoglobin, Sickle; Humans; Patient Reported Outcome Measures; Pyrazines; Pyrazoles; Quality of Life; Retrospective Studies	2022
Reduced red cell transfusions and hospitalizations in sickle cell patients treated with voxelotor-Experience from a single center. Transfusion, 2022, Volume: 62, Issue:7 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Hospitalization; Humans; Pyrazines; Pyrazoles	2022
Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe. European journal of haematology, 2022, Volume: 109, Issue:5 Topics: Anemia, Sickle Cell; Benzaldehydes; Blood Transfusion; Hemoglobin, Sickle; Hemolysis; Humans; Pyrazines; Pyrazoles; Transfusion Reaction	2022
MMW Fortschritte der Medizin, 2022, Volume: 164, Issue:14 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Pyrazines; Pyrazoles	2022
More of the same? Voxelotor spawns a successor, but on what success does it build? British journal of haematology, 2023, Volume: 202, Issue:1 Topics: Anemia, Sickle Cell; Benzaldehydes; Hemoglobin, Sickle; Humans; Pyrazines	2023
Structure-based computational design of novel covalent binders for the treatment of sickle cell disease. Journal of molecular graphics & modelling, 2023, Volume: 124 Topics: Anemia, Sickle Cell; Benzaldehydes; Hemoglobins; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines	2023
Sickle cell drug raises hopes and doubts. Science (New York, N.Y.), 2019, 09-20, Volume: 365, Issue:6459 Topics: Anemia, Sickle Cell; Benzaldehydes; Biomarkers; Drug Approval; Hematologic Agents; Hemoglobins; Humans; Molecular Targeted Therapy; Pyrazines; Pyrazoles; United States; United States Food and Drug Administration	2019
Treating sickle cell anemia: A new era dawns. American journal of hematology, 2020, Volume: 95, Issue:4 Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Child; Fetal Hemoglobin; Forecasting; Gene Expression Regulation; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypoxia, Brain; Infant; P-Selectin; Pain; Pyrazines; Pyrazoles; Therapies, Investigational	2020
Two New Drugs for Sickle Cell Disease. The American journal of nursing, 2020, Volume: 120, Issue:3 Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Drug Approval; Hematologic Agents; Humans; Pyrazines; Pyrazoles; United States; United States Food and Drug Administration	2020
Blocking HbS Polymerization in SCD. Cell, 2020, 03-05, Volume: 180, Issue:5 Topics: Anemia, Sickle Cell; Benzaldehydes; beta-Globins; Hemoglobin, Sickle; Humans; Point Mutation; Polymerization; Pyrazines; Pyrazoles	2020
Two drugs for sickle cell disease. The Medical letter on drugs and therapeutics, 2020, Apr-06, Volume: 62, Issue:1595 Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; Hematologic Agents; Humans; Pyrazines; Pyrazoles	2020
Voxelotor for the Treatment of Sickle Cell Disease. Nursing for women's health, 2020, Volume: 24, Issue:3 Topics: Anemia, Sickle Cell; Benzaldehydes; Hematologic Agents; Humans; Pyrazines; Pyrazoles	2020
Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020, Volume: 39, Issue:9 Topics: Acetamides; Anemia, Sickle Cell; Antihypertensive Agents; Child; Female; Humans; Hypertension, Pulmonary; Prodrugs; Pulmonary Wedge Pressure; Pyrazines	2020
Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes. American journal of clinical pathology, 2020, 10-13, Volume: 154, Issue:5 Topics: Anemia, Sickle Cell; Benzaldehydes; Genotype; Hematologic Agents; Hemoglobin, Sickle; Hemoglobins; Hemoglobins, Abnormal; Humans; Pyrazines; Pyrazoles	2020
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion. Transfusion, 2020, Volume: 60, Issue:12 Topics: Adult; Anemia, Sickle Cell; Benzaldehydes; Combined Modality Therapy; COVID-19; COVID-19 Nucleic Acid Testing; Erythrocyte Transfusion; Female; Hematologic Agents; Hemoglobins; Humans; Hypoxia; Pyrazines; Pyrazoles	2020
A "Split" Hemoglobin S Peak. Clinical chemistry, 2020, 09-01, Volume: 66, Issue:9 Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Chromatography, High Pressure Liquid; Female; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles	2020
Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease. Contemporary clinical trials, 2020, Volume: 98 Topics: Adolescent; Anemia, Sickle Cell; Benzaldehydes; Humans; Pyrazines; Pyrazoles	2020
An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. Biomolecules, 2020, 11-02, Volume: 10, Issue:11 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Erythrocytes; Hemoglobin, Sickle; Hemoglobins; Humans; Pyrazines; Pyrazoles; Structure-Activity Relationship	2020
Yoda1 and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. Scientific reports, 2020, 11-18, Volume: 10, Issue:1 Topics: Anemia, Sickle Cell; Benzophenanthridines; Calcium; Dose-Response Relationship, Drug; Erythrocyte Membrane; Erythrocytes; Humans; Intercellular Signaling Peptides and Proteins; Ion Channels; Phosphatidylserines; Protein Kinase C; Pyrazines; Spider Venoms; Thiadiazoles	2020
The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease. American journal of hematology, 2021, 04-01, Volume: 96, Issue:4 Topics: Acute Pain; Adolescent; Adult; Anemia, Sickle Cell; Benzaldehydes; Child; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Hemoglobin, Sickle; Humans; Incidence; Leg Ulcer; Male; Middle Aged; Pyrazines; Pyrazoles; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult	2021
Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial. British journal of haematology, 2021, Volume: 192, Issue:5 Topics: Acetamides; Anemia, Sickle Cell; Benzaldehydes; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hemoglobins; Hemolysis; Humans; Hydroxyurea; Intermediate-Conductance Calcium-Activated Potassium Channels; Pyrazines; Pyrazoles; Trityl Compounds	2021
Hb S ( Hemoglobin, 2021, Volume: 45, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Chromatography, High Pressure Liquid; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles	2021
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease? The Lancet. Haematology, 2021, Volume: 8, Issue:5 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzaldehydes; Double-Blind Method; Follow-Up Studies; Humans; Pyrazines; Pyrazoles	2021
How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor? Transfusion, 2021, Volume: 61, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Blood Component Removal; Erythrocyte Transfusion; Hematologic Agents; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles	2021
Arriving at a Number: What Hemoglobin S Level to Select During an Emergent RBC Exchange for Patients on Voxelotor. American journal of clinical pathology, 2021, 05-18, Volume: 155, Issue:6 Topics: Anemia, Sickle Cell; Benzaldehydes; Genotype; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles	2021
Time to rethink haemoglobin threshold guidelines in sickle cell disease. British journal of haematology, 2021, Volume: 195, Issue:4 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Blood Transfusion; Blood Viscosity; Genetic Therapy; Hematocrit; Hematopoietic Stem Cell Transplantation; Hemoglobin, Sickle; Hemoglobins; Humans; Hydroxyurea; Practice Guidelines as Topic; Pyrazines; Pyrazoles	2021
Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood, 2021, 09-30, Volume: 138, Issue:13 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Erythrocytes; Hemoglobin, Sickle; Humans; Models, Molecular; Oxygen; Pyrazines; Pyrazoles	2021
Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. American journal of hematology, 2018, Volume: 93, Issue:3 Topics: 2,3-Diphosphoglycerate; Anemia, Sickle Cell; Benzaldehydes; Cerebrovascular Circulation; Cerebrovascular Disorders; Erythrocytes, Abnormal; Hematocrit; Hematologic Agents; Hemoglobin, Sickle; Hemolysis; Humans; Hypoxia; Microcirculation; Models, Biological; Organ Specificity; Oxygen; Oxyhemoglobins; Polymerization; Protein Binding; Pyrazines; Pyrazoles; Risk Assessment	2018
Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data. American journal of hematology, 2018, Volume: 93, Issue:3 Topics: Adult; Anemia, Sickle Cell; Animals; Benzaldehydes; Cerebrovascular Circulation; Child; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Erythropoietin; Gene Knock-In Techniques; Hematologic Agents; Hemoglobin, Sickle; Humans; Hypoxia; Mice; Mice, Transgenic; Oxygen; Polymerization; Pyrazines; Pyrazoles; Reticulocytes	2018
Voxelotor (GBT440) produces interference in measurements of hemoglobin S. Clinica chimica acta; international journal of clinical chemistry, 2018, Volume: 482 Topics: Administration, Oral; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Chromatography, High Pressure Liquid; Hemoglobin, Sickle; Humans; Male; Pyrazines; Pyrazoles	2018
Voxelotor treatment of a patient with sickle cell disease and very severe anemia. American journal of hematology, 2019, Volume: 94, Issue:4 Topics: Adult; Anemia, Sickle Cell; Benzaldehydes; Female; Humans; Pyrazines; Pyrazoles; Severity of Illness Index	2019
Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. American journal of hematology, 2019, Volume: 94, Issue:5 Topics: Anemia, Sickle Cell; Benzaldehydes; Erythrocytes, Abnormal; Hemoglobin, Sickle; Humans; Oxygen; Pyrazines; Pyrazoles	2019
Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia. Bioconjugate chemistry, 2019, 03-20, Volume: 30, Issue:3 Topics: Anemia, Sickle Cell; Antisickling Agents; Benzaldehydes; Erythrocytes; Hemoglobin, Sickle; Humans; Molecular Docking Simulation; Oxygen; Pyrazines; Pyrazoles	2019
Primary polymerization prevention. Blood, 2019, 04-25, Volume: 133, Issue:17 Topics: Anemia, Sickle Cell; Benzaldehydes; Humans; Patients; Polymerization; Pyrazines; Pyrazoles	2019